Okwo 2003 Reference

1 Miller MA, Hinman AR (2004) Economic analysis of vaccine policies. In: SA Plotkin, WA Orenstein (eds): Vaccines, 4th edn. Elsevier Inc., Philadelphia, PA, 1463-1490

2 Bloom DE, Canning D, Weston M (2005) The value of vaccination. World Economics 6: 15-39

3 Keja K, Chan C, Hayden G, Henderson RH (1988) Expanded programme on immunization. World Health Stat Q 41: 59-63

4 Fenner F, Henderson DA, Arita I, Jezek A, Ladnyi ID (1988) Smallpox and its eradication. World Health Organization, Geneva

5 Expanded Programme on Immunisation (2006) Progress towards the global eradication of poliomyelitis, 2005. Wkly Epidemiol Rec 81: 164-172

6 World Health Organization (2005) WHO vaccine-preventable diseases: monitoring system 2005 summary. WHO IVB/2005, Geneva

7 World Health Organization and United Nations Children's Fund (2003) State of the World's Vaccines and Immunization. World Health Organization, Geneva

8 World Health Organization and United National Children's Fund. Global Immunization Vision and Strategy, 2006-2015 (2005) Geneva, Switzerland: World Health Organization and United National Children's Fund. (WHO/ IVB/05.05). Accessed on June 30 at http//:www.who.int/vaccines/GIVS/English/ GIVS_final_17Oct05.pdf

9 Murray CJL, Lopez AD, Mathers CD, Stein C (2001) The Global Burden of Disease 2000 Project: Aims, Methods, and Data Sources (Global Programme on Evidence for Health Policy Discussion Paper No 36).World Health Organization, Geneva

10 World Health Organization (2006) Challenges in global immunization and the global Immunization Vision and Strategy, 2006-2015. Wkly Epidemiol Rec 81: 190-195

11 UNICEF. A world fit for children: Millennium Development Goals (2003) Special session on children documents: the convention on the rights of the child. July 2002. Accessed on June 30, 2006 at www.unicef.org/publications/index_ 4445.html

12 Feudtner C, Marcuse EK (2001) Ethics and immunization policy: promoting dialogue to sustain consensus. Pediatrics 107: 1158-1164

13 Global Alliance for Vaccines and Immunization (2000) Second GAVI Board Meeting, January 2000 (GAVI/00.01). World Health Organization, Geneva

14 Declaration of Alma-Ata (1978) International Conference on Primary Health Care, Alma-Ata, USSR, 6-12 September, 1978

15 World Health Organization (2003) Vaccines, Immunization & Biologicals. Case Information for the Development of Immunization Policy (WH0/V&B/02.28). World Health Organization, Geneva

16 Campbell JD, Burgess M (2004) Heterogeneity of pediatric immunization schedules in industrialized countries. In: MM Levine, JB Kaper, R Rappuoli, MA Liu, MF Good (eds): New Generation Vaccines, 3rd edn. Marcel Dekker, New York

17 Hadler S, Dietz V, Okwo-Bele JM, Cutts FT (2004) Vaccination programs in developing countries. In: SA Plotkin, WA Orenstein (eds): Vaccines, 4th edn. Elsevier, Philadelphia, PA

18 World Health Organization (2005) WHO vaccine preventable diseases monitor ing system:2005 Global summary. Accessed June 30, 2006 at http//:www.who. int/vaccines-documents/globalsummary/globalsummary.pdf

19 Expanded Programme on Immunization (1987) Issues in Neonatal Tetanus Control. World Health Organization, Geneva WHO/EPI/GAG/87/WP.11

20 World Health Organization (2006) Tetanus vaccine. WHO position paper. Wkly Epidemiol Rec 81: 198-208

21 World Health Organization (2000) Sustainable outreach services (SOS): A strategy for reaching the unreached with immunization and other services. WHO/ V&B/00.37. World Health Organization, Geneva

22 Global Tuberculosis Programme and Global Programme on Vaccines (2004) BCG vaccine - WHO position paper. Wkly Epidemiol Rec 79: 27-38

23 Yih WK, Lett SM, des Vignes FN (2000) The increasing incidence of pertussis in Massachusetts' adolescents and adults, 1989-1998. J Infect Dis 182: 1409-1416

24 World Health Organization (2000) Strategies for reducing global measles mortality. Wkly Epidemiol Rec 75: 409-416

25 Expanded Programme on Immunization (2006) Progress in reducing global measles deaths, 1999-2004. Wkly Epidemiol Rec 81: 90-94

26 Ching P, Birmingham M, Goodman T (2000) Childhood mortality impact and costs of implementing vitamin A supplementation in immunization campaigns. Am J Public Health 90: 1526-1529

27 Centers for Disease Control and Prevention (2005) Distribution of insecticide-treated bednets during an integrated nationwide immunization campaign - Togo, West Africa, December 2004. MMWR 54: 994-996

28 Taylor C, Cutts F, Taylor ME (1997) Ethical dilemmas in current planning for polio eradication. Am J Public Health 87: 922-925

29 Taylor Commission (1995) The Impact of the Expanded Program on Immunization and the Polio Eradication Initiative on Health Systems in the Americas. Pan American Health Organization, Washington, DC

30 Loevinsohn B, Aylward B, Steinglass R, Ogden E, Goodman T, Melgaard B (2002) Impact of targeted programs on health systems: A case study of the Polio Eradication Initiative. Am J Public Health 92: 19-23

31 World Health Organization Expanded Programme on Immunization and United Nations Children's Fund (2000) Product Information Sheets, 2000. World Health Organization, Geneva. WHO document WHO/V&B/00.13.

32 WHO and UNICEF (1999) Quality for the Cold Chain - WHO/UNICEFpolicy statement on the use of vaccine vial monitors in immunization practice. World Health Organization, Geneva, WHO/V&B99.18

33 Nelson CM, Wibisono H, Purwanto H, Mansyur I, Moniaga V, Widjaya A (2004) Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions. Bull World Health Organ 82: 99-105

34 World Health Organization (2006) Global Advisory Committee on Vaccine Safety, 1-2 December 2005. Wkly Epidemiol Rec 81:15-19

35 Expanded Programme on Immunisation (1993) Surveillance of Adverse Events Following Immunization: Field Guide for Managers of Immunization Programmes. World Health Organization, Geneva (WHO/EPI/TRAM/93.2)

36 Folb PI, Bernatowska E , Chen R, Clemens J, Dodoo ANO, Ellenberg SS, Farrington P, John TJ, Lambert PH, MacDonald NE et al (2004) A global per-

spective on vaccine safety and public health: the Global Advisory Committee on Vaccine Safety. Am J Public Health 94:1926-1931

37 Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M (1999) Unsafe injections in the developing and the transmission of bloodborne pathogens: a review. Bull World Health Organ 77: 789-798

38 Anonymous (1999) Safety of injections. WHO-UNICEF-UNFPA joint statement on the use of auto-disable syringes in immunization services. World Health Organization, Geneva, WHO/ V&B/99.25

39 Duclos P, Delo A, Aguado T, Bilous J, Birmingham M, Kieny MP, Milstien J, Wood D, Tarantola D (2003) Immunization safety priority project at the World Health Organization. Semin Pediatr Infect Dis 14: 233-239

40 Henderson R, Keja J (1989) Global control of vaccine-preventable diseases: how progress can be evaluated. Rev Infect Dis 11 (Suppl): S649-S654

41 World Health Organization (2005) Vaccines, Immunization & Biologicals. WHO/UNICEF Joint Reporting Form on Vaccine Preventable Diseases, 2005. Accessed on the internet June 30, 2006 at www.who.int/immunization_ monitoring/Jomt_reportmg/en/mdex.html

42 Henderson RH, Sundaresan T (1982) Cluster sampling to assess immunization coverage: a review of experience with a simplified sampling method. Bull World Health Organ 60: 253-260

43 de Quadros, CA, Hersh BS., Olive JM (1997) Eradication of wild poliovirus from the Americas: acute flaccid paralysis surveillance, 1988-1995. J Infect Dis 175 (Suppl 1): S37-S42

44 WHO and UNICEF (2005) WHO/UNICEF Joint statement: global plan for reducing measles mortality 2006-2010. Geneva (WHO/IVB/05.11)

45 World Health Organization (2005) World Health Report 2005. Statistical Annex Tables 3 + 4, 191-192

46 World Health Organization (2005) Laboratory surveillance for wild and vaccine-derived polioviruses, January 2004-June 2005. Wkly Epidemiol Rec 80: 333-340

47 Bresee JS, Glass RI, Fang ZY(2004) First report from the Asian Rotavirus Surveillance Network. Emerg Infect Dis J 10: 988-995

48 World Health Organization (2004) Acute flaccid paralysis surveillance: a global platform for detecting and responding to priority infectious diseases. Wkly Epidemiol Rec 79: 425-433

49 World Health Organization (2006) Challenges in global immunization and the Global Immunization Vision and Strategy 2006-2015. Wkly Epidemiol Rec 81: 190-195

50 Hardy I, Dittman S, Sutter R (1996) Current situation and control strategies for resurgence of diphtheria in newly independent states of the former Soviet Union. Lancet 347: 1739-1744

51 Tangermann RH, Hull HF, Jafari H, Nkowane B, Everts H, Aylward RB (2000) Eradication of poliomyelitis in countries affected by conflict. Bull World Health Organ 78: 330-338

52 Gwatkin D, Davidson A, Yazbeck A, Wagstaff A (eds) (2005) Reaching the Poor with Health, Nutrition and Population Services: What Works, What Doesn't, and Why. World Bank, Washington, D.C.

53 Technical consultation on imbalances in the health workforce (2002) WHO/ EIP/OSD/02.3. World Health Organization, Geneva

54 World Health Organization (2000) Key elements for improving supplementary immunization activities for polio eradication. World Health Organization, Geneva WH0/V&B/00.22

55 World Health Assembly (1988) Global eradication of poliomyelitis by the year 2000. World Health Organization, Geneva (Resolution WHA41.28)

56 Dowdle WR, Cochi SL (2002) Global eradication of poliovirus: history and rationale. In: BL Semler, E Wimmer (eds): Molecular biology of picornaviruses. ASM Press, Washington, DC

57 World Health Organization (2001) Transmission of wild poliovirus type 2: apparent global interruption. Wkly Epidemiol Rec 76: 95-97

58 Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA (2005) Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol 59: 587-635

59 Dowdle WR, Hopkins DR (1998) The Eradication of Infectious Diseases: Dahlem Workshop Report. John Wiley & Sons, Chichester

60 De Quadros CA, Olive JM, Hersh BS (1996) Measles elimination in the Americas: evolving strategies. JAMA 275: 224-229

61 Expanded Programme on Immunisation (2006) Progress in reducing global measles deaths, 1999-2004. Wkly Epidemiol Rec 81: 90-94

61a Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS (2007) Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 369: 165-166

62 WHO and UNICEF (2005) WHO/UNICEF Joint Statement: Global plan for reducing measles mortality 2006-2010. Geneva (WHO/IVB/05.11)

63 PAHO (2004) XVI Meeting of the Technical Advisory Group on Vaccine Preventable Diseases, Mexico City. 3-5 November 2004. Final Report. Accessed June 30 at http://www.paho.org/English/AD/FCH/IM/TAG16_FinalReport_ 2004.pdf

64 World Health Organization (1999) Progress towards the global elimination of neonatal tetanus, 1990-1998. Wkly Epidemiol Rec 74: 73-80

65 Vandelaer J, Birmingham M, Gasse F, Kurian M, Shaw C, Garnier S (2003) Tetanus in developing countries: an update on the maternal and neonatal tetanus elimination initiative. Vaccine 21: 3442-3445

66 Adegbola RA, Secka O, Lahai G (2005) Elimination of Haemophilus influenzae type b (Hib) disease from the Gambia after the introduction of routine immunization with a Hib conjugate vaccine: a prospective study. Lancet 366: 144-150

67 Steinhoff MC (1997) Haemophilus influenzae type b infections are preventable everywhere. Lancet 349: 1186-1187

68 de Andrade AL, de Andrade JG, Martelli CM, e Silva SA, de Oliveira RM, Costa MS, Laval CB, Ribeiro LH, Di Fabio JL (2004) Effectiveness of Haemophilus influenzae b conjugate vaccine on childhood pneumonia: a case-control study in Brazil. Int J Epidemiol 33: 173-178

69 Gessner BD, Sutanto A, Linehan M (2005). Incidences of vaccine-preventable

Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomized vaccine-probe trial. Lancet 365: 43-52

70 World Health Organization (2006) Conclusions and recommendations from the Strategic Advisory Group of Experts to the Department of Immunization, Vaccines and Biologicals. Wkly Epidemiol Rec 81: 2-11

71 Kane MA, Clements J, Hu D (1993) Hepatitis B. In : DT Jamison, WH Mosley, AR Measham, J Bobadilla (eds): Disease Control Priorities in Developing Countries. Oxford University Press, New York, 321-330

72 Van Damme P, Kane M, Meheus A (1997) Integration of hepatitis B vaccination into national immunization programmes. BMJ 314: 1033-1037

73 Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY, Chen DS (1997) Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336:1855-1859

74 Margolis HS, Alter MJ, Hadler SC (1991) Hepatitis B: evolving epidemiology and implications for control. Semin Liver Dis 11: 84-92

75 Chen HL, Chang MH, Ni YH, Hsu HY, Lee PI, Lee CY, Chen DS (1996) Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan. JAMA 276: 906-908

76 World Health Organization (2006) Progress in the control of yellow fever in Africa. WHO Wkly Epidemiol Rec 80: 50-54

77 World Bank (1993) World development report 1993: investing in health. Oxford University Press, New York

78 Monath TP, Nasidi A (1993) Should YF vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria, Am J Trop Med Hyg 48: 274-299

79 Williams BG, Gouws E, Boschi-Pinto C, Bryce J, Dye C (2002) Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2: 25-32

80 Madhi SA, Peterson K, Madhi A, Wasas A, Klugman KP (2000) Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 19: 1141-1147

81 Fedson DS, Musher DM (2004) Pneumococcal polysaccharide vaccine. In: S Plotkin, W Orenstein (eds): Vaccines, 4th edn. Saunders, Philadelphia, 529-588

82 Whitney CG, Farley MM, Hadler J (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348: 1737-1746

83 Centers for Disease Control and Prevention (CDC) (2005) Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease: United States, 1998-2003. MMWR Morb Mortal Wkly Rep 54: 893-897

84 Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB (2006) Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5

years of use in the United States incorporating herd effects. Pediatr Infect Dis J 25: 494-501

85 Salo H, Sintonen H, Kilpi T, Linna M, Nohynek H, Verho J, Nuorti PJ (2005) Economic evaluation of pneumococcal conjugate vaccination in Finland. Scand Infect Dis J 37: 821-832

86 Dagan R (2004) The potential of pneumococcal conjugate vaccines to reduce antibiotic resistance. Adv Expe Med Biol 549: 211-219

87 Cutts FT, Zaman SM, Enwere G (2005) Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. Lancet 365: 1139-1146

88 Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB (2006) Pneumococcal vaccination in developing countries. Lancet 367: 1880-1882

89 Schmitt HJ, Booy R, Weil-Olivier C, Van Damme P, Cohen R, Peltola H (2003) Child vaccination policies in Europe: a report from the Summits of Independent European Vaccination Experts. Lancet Infect Dis 3: 103-108

90 Baltimore RS (2006) Recent trends in meningococcal epidemiology and current vaccine recommendations. Curr Opin Pediatr 18: 58-63

91 Centers for Disease Control and Prevention (CDC) (2005) Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 54 (RR-7): 1-21

92 World Health Organization (2005) World Health Report 2004. WHO, Geneva

93 Baseman JG, Koutsky LA (2005) The epidemiology of human papillomavirus infections. J Clin Virol 32S: S16-S24

94 Parikh S, Brennan P, Boffetta P (2003) Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 105: 687-691

95 Jansen KU, Shaw AR (2004) Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 55: 19-31

96 Fine PE (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346: 1339-1345

97 Kaufmann SH (2006) Envisioning future strategies for vaccination against tuberculosis. Nat Rev Immunol 6: 699-704

Pediatric Infectious Diseases Revisited ed. by Horst Schroten and Stefan Wirth © 2007 Birkhäuser Verlag Basel/Switzerland

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment